Nickeleit Irina, Zender Steffen, Kossatz Uta, Malek Nisar P
Institute for Molecular Biology, Hannover Medical School, Hannover, Germany.
Cell Div. 2007 May 9;2:13. doi: 10.1186/1747-1028-2-13.
The cyclin kinase inhibitor p27kip1 acts as a potent tumor supressor protein in a variety of human cancers. Its expression levels correlate closely with the overall prognosis of the affected patient and often predict the outcome to different treatment modalities. In contrast to other tumor suppressor proteins p27 expression levels in tumor cells are frequently regulated by ubiquitin dependent proteolysis. Re-expression of p27 in cancer cells therefore does not require gene therapy but can be achieved by interfering with the protein turnover machinery. In this review we will summarize experimental results which highlight the potential use of p27 as a target for oncological therapies.
细胞周期蛋白激酶抑制剂p27kip1在多种人类癌症中作为一种有效的肿瘤抑制蛋白发挥作用。其表达水平与受影响患者的总体预后密切相关，并且常常能预测不同治疗方式的结果。与其他肿瘤抑制蛋白不同，肿瘤细胞中p27的表达水平常常受到泛素依赖性蛋白水解作用的调控。因此，在癌细胞中重新表达p27不需要基因治疗，而是可以通过干扰蛋白质周转机制来实现。在这篇综述中，我们将总结实验结果，这些结果突出了p27作为肿瘤治疗靶点的潜在用途。
